Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, T-Cell, Peripheral 12Lymphoma, T-Cell 6Recurrence 5Lymphoma 5Lymphoma, Non-Hodgkin 4Sezary Syndrome 2Neoplasm Metastasis 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, B-Cell 2Immunoblastic Lymphadenopathy 2Hodgkin Disease 2Carcinoma, Non-Small-Cell Lung 2Waldenstrom Macroglobulinemia 1Urinary Bladder Neoplasms 1Smoking 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoproliferative Disorders 1Lymphoma, Primary Cutaneous Anaplastic Large Cell 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, Extranodal NK-T-Cell 1Lung Neoplasms 1Leukemia-Lymphoma, Adult T-Cell 1Leukemia 1Hematologic Neoplasms 1

Interventions

aflibercept 4epratuzumab 2Radioimmunodetection 2ontuxizumab 1Methotrexate 1Fentanyl 1Cyclosporine 1BI 2536 190Y-octreotide, DOTA-Tyr(3)- 110-propargyl-10-deazaaminopterin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Lymphoma, Large-Cell, Immunoblastic × 10-propargyl-10-deazaaminopterin × Clear all
NCT00052442 2021-08-25

10-Propargyl-10-Deazaaminopterin in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma

Spectrum Pharmaceuticals, Inc

Phase 1/2 Completed
72 enrolled 12 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Hodgkin Disease, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡